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Abstract
Cardiac involvement in neuromuscular disease most often manifests with cardiomyopathy, atrioventricular conduction 
disturbances, and supraventricular and ventricular tachyarrhythmias, accompanied by heart failure in some patients. 
The phenotype of cardiac involvement, and to a large extent also the symptoms and the timing of their occurrence, 
depend on the genetic background of the neurological disease, hence the importance of genetic testing. Knowledge of 
the proper neurological diagnosis supported by genetic testing results allows for targeted cardiological investigations. 
Non-invasive imaging modalities (echocardiography, cardiac magnetic resonance) and cardiac rhythm monitoring using 
electrocardiography allow the assessment of myocardial involvement progression and implementation of appropriate 
treatment. In addition, they enable identification of asymptomatic patients at an early disease stage and prevention of 
future sudden cardiac death.
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Introduction
Neuromuscular diseases (NMD) are a wide group of disor-
ders with varying clinical phenotypes. Peripheral muscle 
dysfunction is often accompanied by abnormal myocardial 
structure and function, particularly in patients with vario-
us types of muscular dystrophy. In the recent decades, 
our knowledge on the genetic defect underlying most 
muscular dystrophies has expanded significantly. Of inte-
rest, the same mutations may be associated with various 
phenotypes, including isolated cardiomyopathies without 
peripheral muscular symptoms [1]. In most muscular dys-
trophies, cardiac involvement manifests as various types of 
cardiomyopathy, with or without symptomatic heart failure, 
atrioventricular conduction disturbances, and atrial and 
ventricular tachyarrhythmias (Table 1). Cardiac involvement 
manifesting during childhood or in the first three decades 
of life is typical for many NMD. However, cardiac symptoms 
may also develop much later, or precede the diagnosis 
of NMD in some relatively low-symptomatic neurological 
syndromes. Some NMD are associated with a high risk of 
sudden cardiac death (SCD). Others, despite evidence of 
advanced cardiac involvement, are not associated with 
an increased SCD risk, and the cause of death is usually 
respiratory failure or other organ damage. In addition to 
appropriate neurological phenotypic characterization, an 
attempt to make the genetic diagnosis is of key importan-
ce in NMD. Early detection of mutations predisposing to 
the development of cardiomyopathy or conduction distur-
bances should prompt appropriate investigations and 
prevention of life-threatening arrhythmia. Of note, with non-
-invasive modalities to evaluate myocardial function, such
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Echocardiography Cardiac magnetic resonance Annual follow-up (including asymptomatic 
disease stage with normal ECG)
Annual TTE Indicated if echocardiography 
not diagnostic and to evaluate 
fibrosis at an early stage
Depending on symptom frequency:
• 24-h/48-h/7-day Holter monitoring
• 14–30-day external loop recorder
• implantable loop recorder
Table 1. Most common types of neuromuscular disease and associated cardiac complications





Cardiomyopathy AV conduction disturbances Arrhythmia
DMD Dystrophin XR DCM Rare Common mild
BMD Dystrophin XR DCM Rare Common
EDMD 1 Emerin XR CM Common Common
EDMD 2 Lamin A/C AD DCM Common Common
DM 1 Protein kinase AD Rarely HCM/DCM Common Common
LGMD 1B Lamin A/C AD DCM Common Common
LGMD 2E B-sarcoglycan AR DCM Common Common
FA Frataxin AR HCM Rare Common
NMD — neuromuscular disease; DMD — Duchenne muscular dystrophy; BMD — Becker muscular dystrophy; EDMD — Emery-Dreifuss muscular dystrophy; DM — myotonic dystrophy; LGMD — limb-girdle 
muscular dystrophy; FA — Friedreich ataxia; CM — cardiomyopathy; DCM — dilated cardiomyopathy; HCM — hypertrophic cardiomyopathy; XR — X-linked; AD — autosomal dominant; AR — autosomal recessive; 
AV — atrioventricular
as echocardiography, cardiac magnetic resonance (CMR) 
and electrocardiography (ECG), it is possible to identify car-
diac dysfunction prior to any cardiovascular symptoms [2] 
(Figure 1). In the present review, we focused on selected is-
sues related to cardiac involvement in dystrophinopathies, 
laminopathies, and myotonic dystrophy (DM).
Dystrophinopathies
Duchenne muscular dystrophy (DMD) is the most com-
mon NMD. It is an X-linked disorder with the incidence of 
1:3600–1:9300 births among males. The genetic defect 
usually involves deletion of multiple exons of the dystrophin 
gene on chromosome X. Due to frame shift, dystrophin is 
virtually absent. In Becker muscular dystrophy (BMD), dys-
trophin gene mutation usually does not lead to frame shift 
and the gene is translated, leading to a partially functional 
protein, although present in lesser amounts. This results in 
a much milder clinical course of muscular dystrophy, and 
usually much later onset of cardiomyopathy. The incidence 
of BMD is also much lower (1:18,000).
DMD
Myocardial involvement in DMD manifests with dilated car-
diomyopathy (DCM). The mean age at the onset of systolic 
dysfunction is about 14 years [3], and development of heart 
failure symptoms is usually delayed, which may be explai-
ned by limited activity of the patients. Cardiac investigations 
should be initiated at the time of the diagnosis of DMD 
[4] and should also target mutation carriers, i.e., mothers 
and sisters of DMD patients, as systolic dysfunction and 
evidence of myocardial fibrosis can usually be identified in 
them in the fifth decade of life [5]. Despite severe systolic 
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dysfunction present in DMD, ventricular arrhythmia is less 
frequent than might be expected, which may be partially 
explained by lower sympathetic tone in these patients. 
Atrioventricular conduction disturbances, typical for some 
NMD, are also very rare in this disorder.
BMD
In most patients with BMD, initial manifestations of car-
diac involvement develop after 20 years of age but they 
are present in 70% of patients by the age of 40 [6]. The 
clinical phenotype is of DCM with varying severity of heart 
failure symptoms. The clinical course of BMD is much less 
predictable compared to DMD. There is no simple correla-
tion between the severity of DCM and peripheral muscle 
involvement. In addition, the risk of SCD seems higher in 
BMD compared to DMD, which may only be partially expla-
ined by earlier development of respiratory failure in DMD, 
potentially leading to earlier death. As a result, patients 
with BMD-related cardiomyopathy are much more often 
referred for implantation of a cardioverter-defibrillator (ICD).
Laminopathies
Emery-Dreifuss muscular dystrophy (EDMD) is a rare form of 
NMD (incidence about 1:100,000 births) characterized by 
an early presence of joint contractures, slowly progressing 
muscle weakness and associated atrioventricular con-
duction disturbances. The underlying genetic defect may 
involve various proteins of the nuclear envelope. Several 
subtypes have been defined, and the most common ones 
are EDMD 1 due to emerinopathies (caused by mutations 
in the EMD gene) and laminopathies (caused by mutations 
in the LMNA gene).
EDMD 1
EDMD 1 is an X-linked disorder. The clinical course is ini-
tially mild. Sometimes the correct neurological diagnosis 
is only made after an advanced atrioventricular block de-
velops in a young man without conventional cardiovascular 
risk factors. Atrioventricular conduction disturbances are 
usually accompanied by junctional escape rhythm and atrial 
standstill, often preceded by low-amplitude atrial fibrillation 
(AF) [7]. In the early disease phase (usually second to third 
decade of life), patients require cardiac pacing without a de-
fibrillator, as the risk of malignant ventricular arrhythmia 
is initially not high [6]. With disease progression, fibrosis 
may progress and involve not only atria but also ventricles, 
ultimately leading to the typical DCM phenotype. At that 
stage, the risk of ventricular arrhythmia is high enough to 
warrant consideration of ICD implantation. The disease is 
associated with significant atrial enlargement, predispo-
sing to supraventricular arrhythmia. As a result, the risk of 
thromboembolic complications including ischaemic stroke 
is significantly increased [8].
EDMD 2
This type of dystrophy is usually characterized by an au-
tosomal dominant mode of inheritance. A defect in the 
lamin A/C gen may also lead to a phenotype of isolated 
DCM with particularly poor prognosis resulting from a high 
rate of SCD. A similar genetic defect was identified in one 
type of limb-girdle muscular dystrophy (LGMD 1B) [9]. The 
neurological phenotype is the same in both most common 
forms of EDMD, while the cardiac presentation varies. 
EDMD 2 is usually characterized by DCM with a relatively 
modest left ventricular chamber enlargement despite se-
vere systolic dysfunction, accompanied by atrioventricular 
conduction disturbances. This type of EDMD is associated 
with a high risk of tachyarrhythmia-related SCD, usually 
due to ventricular fibrillation (VF) [6]. In all patients with 
this type of muscular dystrophy, SCD risk should be evalu-
ated using available tools including dedicated calculators 
[10, 11] (Table 2).
Myotonic dystrophy
Myotonic dystrophy is one of the most common (incidence 
1:8,000 births) muscular dystrophies, most typically ma-
nifesting with myotonia, or impaired muscle relaxation, 
which accompanies muscle weakness and atrophy, and 
symptoms from other organ systems (glaucoma, frontal 
hair loss, hormonal disturbances). The mode of inheritance 
is autosomal dominant. The risk of cardiac complications 
depends on the type of DM.
DM 1
In the more common type 1, the defect involves the DMPK 
gene coding for a protein kinase, and it is characterized 
by trinucleotide triplet expansion. Genetic anticipation can 
be seen, with increasing symptom severity in successive 
generations due to prolongation of repeated sequences. 
In this type of DM, cardiac involvement is seen in about 
80% of patients. Atrioventricular and intraventricular con-
duction disturbances are most commonly accompanied 
by supraventricular and ventricular tachyarrhythmias [12] 
(Table 1). Cardiomyopathy, usually of the DCM phenotype, 
is relatively rare.
DM 2
In this type, the defect involves the CNBP gene which en-
codes a zinc finger protein. Trinucleotide triplet expansion 
is also present but without evident genetic anticipation. 
The clinical presentation is more heterogeneous compared 
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to type 1 but usually milder, with a lower risk of cardiac 
involvement which is seen in up to 10–20% cases. Typical 
cardiac manifestations include first-degree atrioventricular 
block and bundle branch blocks [13].
Cardiac tests in patients  
with NMD
Imaging is necessary to identify myocardial involvement, 
assess its progression, and select patients for implantation 
of cardiac devices. Echocardiography or CMR is recom-
mended upon the diagnosis of NMD due to the possibility 
of an low-symptomatic course of cardiac involvement. If 
no abnormalities are found, imaging should be repeated 
anually or ever 1–5 years [4, 14]. Due to concomitant chest 
deformities and poor acoustic windows, mostly in DMD, 
echocardiography is often not fully diagnostic and CMR is 
warranted. The latter modality is also dedicated for patients 
with identified mutations but no abnormalities found on 
echocardiography. To detect supraventricular or ventricular 
arrythmia that may be associated with a risk of SCD, follow-
-up ECG monitoring should be performed annually since the 
diagnosis of NMD [4, 15]. Depending on the frequency of 
symptoms suggesting arrhythmia which was not recorded 
in conventional ECG, options include 24-hour, 48-hour, or 
7-day Holter ECG monitoring, 14- to 30-day monitoring with 
an external loop recorder, or an implantable loop recorder 
[15] (Table 3).
Drug therapy in patients  
with cardiac involvement in NMD
Few data are available to support the use of typical drug 
therapy recommended in heart failure or asymptoma-
tic left ventricular systolic dysfunction in patients with 
NMD-related cardiomyopathies. There is some evidence 
indicating that angiotensin-converting enzyme (ACE) 
inhibitors and corticosteroids (used to improve muscle 
strength and prevent cardiomyopathy) are warranted in 
patients with DMD. However, most recommendations are 
based on extrapolating data from the general population 
of patients with heart failure of various aetiology to the 
NMD populations. Currently, ACE inhibitors are recom-
mended in all patients with NMD and reduced left ventri-
cular ejection fraction (LVEF) and should be considered 
in boys above 10 years of age with DMD for the primary 
prevention of DCM [4].
There is a consensus that beta-blockers should be used 
in patients with NMD and existing systolic dysfunction, and 
in patients with cardiac arrhythmia to relieve symptoms re-
lated to tachyarrythmias. However, beta-blockers are gene-
rally not recommended solely for the prevention of systolic 
dysfunction or symptomatic heart failure in patients without 
existing left ventricular systolic dysfunction.
Based on promising data on the effectiveness of combi-
ned aldosterone antagonist and ACE inhibitor treatment in 
patients with DMD and concomitant left ventricular systo-
lic dysfunction, such a combination should be considered 
in patients with DMD/BMD who fulfil the above criterion. 
It may also be considered in those with preserved systolic 
function and myocardial fibrosis identified in CMD [4]. Of 
note, the above recommendations apply only to patients 
with dystrophinopathies.
Similarly, glucocorticosteroids may be considered to 
delay progression of cardiac involvement in a limited po-
pulation of patients with DMD.
Based on the current recommendations, anticoagula-
tion in NMD should be limited to patients with established 
indications for such treatment (e.g., presence of an intra-
cardiac thrombus), and may be considered in patients with 
documented AF. The role of commonly used scoring systems 
for the risk of thromboembolic complication, and of novel 
oral anticoagulants has not been established in the NMD 
population. In the clinical practice, patients above 30 years 
of age with EDMD and concomitant AF, atrial flutter or atrial 
standstill receive anticoagulation due to markedly increa-
sed stroke risk regardless of the risk estimation using the 
CHA2DS2-VASc score (Table 4).
Table 2. Evaluation of the risk of life-threatening tachyarrhythmia in laminopathies (from [10])
Parameter Evaluation
Gender [M/F] Higher risk in men
Non-missense LMNA gene mutation [yes/no] Insertions, deletions, truncation mutations, abnormal splicing
AVB [no/1st degree AVB/advanced AVB] The highest degree of AVB should be taken into account. First-degree AVB is defined 
as PR interval ≥ 0.2 s, and advanced AVB is defined as second-degree Mobitz II AVB 
or third-degree AVB (but not second-degree Mobitz I AVB)
nsVT [yes/no] ≥ 3 ventricular beats ≥ 120/min and duration < 30 s during Holter ECG monitoring 
for a minimum of 24 h
LVEF [%] Echocardiographic measurement
M — male; F — female; AVB — atrioventricular block; nsVT — nonsustained ventricular tachycardia; LVEF — left ventricular ejection fraction; ECG — electrocardiography
247www.journals.viamedica.pl/folia_cardiologica
Michał Marchel et al., Cardiac diagnostics in neuromuscular diseases
Table 3. The 2005 European Society of Cardiology (ESC) recommendations of arrhythmia treatment in patients with neuromuscular 
disease (from [15])
Recommendation Class of recom-
mendations
Level of  
evidence
Annual follow-up is recommended in patients with muscular dystrophies, even in the concealed 
phase of the disease when patients are asymptomatic and the ECG is normal
I B
It is recommended that patients with NMD who have ventricular arrhythmia are treated in the 
same way as patients without NMD
I C
Permanent pacemaker implantation is recommended in patients with NMD diseases and third-
-degree or advanced second-degree AVB at any anatomical level
I B
Permanent pacemaker implantation may be considered in patients with DM type 1 (Steinert 
disease), Kearns–Sayre syndrome or LGMD with any degree of AVB (including first-degree) in consi-
deration of the risk of rapid progression
IIb B
The use of an ICD may be considered in DM type 1 (Steinert disease), EDMD and LGMD type 1B 
when there is an indication for pacing and evidence of ventricular arrhythmias
IIb B
ECG — electrocardiography; NMD — neuromuscular disease; AVB — atrioventricular block; DM — myotonic dystrophy; LGMD — limb-girdle muscular dystrophy; EDMD — Emery-Dreifuss muscular dystrophy
Table 4. Indications for cardiac treatment in patients with neuromuscular disease
Type of therapy Indicated May be considered Not recommended
Drug therapy ACEI LVEF ≤ 35%
DMD > 10 years of age
MRA DMD/BMD + LV systolic dysfun-
ction (in combination with ACEI)
DMD/BMD + preserved LV 
systolic function when fibrosis 
present on CMR
BB Systolic dysfunction, symptomatic 
tachyarrhythmia
Prevention of systolic 
dysfunction, symp-
tomatic HF without 
systolic dysfunction
GCS DMD + to delay progression  
of cardiac involvement
AC Depending on the risk of thrombo-
embolic complications; documen-
ted intracardiac thrombus; docu-
mented AF or atrial flutter
EDMD + AF, atrial flutter, atrial 
standstill > 30 years of age
Conventional pacing Symptomatic bradyarrhythmia, AV 
conduction disturbances (absolute 
indications: asymptomatic third 
degree or second degree Mobitz II 
AV block)
DM 1, LGMD, EDMD + symp-
tomatic second degree Mobitz I  
or first degree AV block
Cardiac device ICD Symptomatic HF with NYHA class 
II–III symptoms, LV systolic dysfun-
ction, LVEF ≤ 35%, high SCD risk
CRT QRS ≥ 130 ms + LBBB (in SR) par-
ticularly in EDMD, BMD, DM 1
QRS ≥ 130 ms without LBBB  
(in SR) or with AF
Ventricular assist device Destination therapy in selected 
situations in DMD
Cardiac transplantation Mild changes in peripheral muscle, 
preserved respiratory function
ACEI — angiotensin-converting enzyme inhibitors; LVEF — left ventricular ejection fraction; DMD — Duchenne muscular dystrophy; MRA — mineralocorticoid receptor antagonists; BMD — Becker muscular 
dystrophy; LV — left ventricle; CMR — cardiac magnetic resonance; BB — beta-blockers; HF — heart failure; GCS — glucocorticosteroids; AC — anticoagulants; AV — atrioventricular; DM — myotonic dystrophy; 
LGMD — limb-girdle muscular dystrophy; EDMD — Emery-Dreifuss muscular dystrophy; AF — atrial fibrillation; ICD — implantable cardioverter-defibrillator; NYHA — New York Heart Association; SCD — sudden 
cardiac death; CRT — cardiac resynchronization therapy; LBBB — left bundle branch block; SR — sinus rhythm
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Conventional pacing
Candidates for permanent cardiac pacing include patients 
with symptomatic bradycardia due to sinus node disease 
or atrioventricular block [15]. In the population with NMD, 
atrioventricular conduction disturbances are more common 
in patients with EDMD, DM and LGMD, and cardiac pacing 
should be considered at the initial manifestation (usually 
below 30 years of age). It should be remembered, howe-
ver, that pacemaker implantation in patients with EDMD 
does not protect from stroke due to the occurrence of AF 
or atrial standstill. In patients with bradycardia and AF, 
rate adaptive ventricular pacing should be preferred over 
dual-chamber pacing.
Implantable cardiac devices  
(cardioverter defibrillator,  
cardiac resynchronization therapy)
Typical indications for ICD implantation for primary pre-
vention of SCD are present in optimally managed patients 
with symptomatic heart failure with New York Heart Asso-
ciation (NYHA) class II–III symptoms and left ventricular 
systolic dysfunction with LVEF ≤ 35% [16]. In general, the 
same indications apply to the NMD population. The final 
decision, however, should also take into account specific 
circumstances in these patients, including life expectan-
cy, potentially futile care in end-stage disease, risk of 
procedural complications, and the risk of inappropriate 
ICD interventions. The neurological diagnosis, genetic 
defect, or even mutation type in a given patient should 
also be considered, as these may indicate a particularly 
high SCD risk. In summary, ICD implantation should be 
considered in selected patients with DMD, BMD, EDMD 
2, LGMD 1B, DM 1, and Friedreich ataxia, taking into 
account the above risk factors. Cardiac resynchroniza-
tion therapy (CRT) may be considered in patients with 
indications for permanent pacing, systolic dysfunction, 
and predicted high percentage of pacing, particularly in 
EDMD, BMD, and DM 1.
Other options
In some patients, particularly with EDMD 2, LGMD 1B and 
BMD, cardiac transplantation may be considered if pe-
ripheral muscle changes are not advanced and respiratory 
function is preserved. There are also single reports of the 
use of ventricular assist devices as destination therapy in 
patients with DMD. Integrated palliative care is recommen-
ded in end-stage heart failure.
Summary
Most patients with NMD are at risk of cardiac involvement. 
Precise neurological diagnosis is vital for early determi-
nation of this risk and implementation of appropriate 
treatment, including therapies to delay the development 
of cardiomyopathy. Early imaging using echocardiography 
or CMR and systematic monitoring of the progression of 
myocardial involvement are necessary to guide decisions 
regarding initiation of drug treatment and therapies to 
prevent SCD. The risk of cardiac complications, and thus 
management may vary significantly depending on the 
underlying genetic defect despite similar or even identical 
phenotypic presentation. Both effective drug therapy and 
invasive procedures that modify outcomes in many NMD 
are currently available. Neurological units involved in the 
diagnosis and management of NMD should cooperate with 
adequately prepared cardiologists experienced in managing 
NMD patients.
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Streszczenie
Zajęcie mięśnia sercowego w przebiegu chorób nerwowo-mięśniowych najczęściej objawia się pod postacią kardiomio-
patii, zaburzeń przewodnictwa przedsionkowo-komorowego oraz tachyarytmii nadkomorowych i komorowych, przebiega-
jących niekiedy z niewydolnością serca. Fenotyp zajęcia serca, a w dużej mierze również objawy i czas ich wystąpienia, 
zależą od podłoża genetycznego choroby neurologicznej, dlatego należy podkreślić istotę badań genetycznych. Znajo-
mość właściwego rozpoznania neurologicznego popartego wynikiem badań genetycznych pozwala na ukierunkowaną 
diagnostykę kardiologiczną. Nieinwazyjne badania obrazowe (echokardiografia, rezonans magnetyczny serca) oraz 
monitorowanie rytmu serca za pomocą elektrokardiografii pozwalają na ocenę progresji zajęcia mięśnia sercowego 
i wdrożenie odpowiedniego leczenia. Co więcej, umożliwiają wychwycenie pacjentów bezobjawowych na wczesnym 
etapie choroby i prewencję wystąpienia nagłego zgonu sercowego w przyszłości.
Słowa kluczowe: dystrofia mięśniowa, kardiomiopatie, zaburzenia przewodnictwa, dystrofinopatie, laminopatie, 
dystrofia miotoniczna
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Commentary
dr hab. n. med. Piotr Bienias●iD 
Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland
The article “Cardiac evaluation in patients with neuromuscular diseases” deals with an important is-
sue in specialist cardiology practice. Individuals with neuromuscular diseases are a heterogeneous 
group of patients with various clinical presentation in terms of both neurological symptoms and po-
tential cardiovascular complications.
While the knowledge on specific neuromuscular disorders is well established among the neurologists, in the 
cardiology practice these patients may be collectively referred to as “patients with dystrophy”, without de-
tailed differentiation between different types. Obviously, this may be sometimes justified and explained by the organization of health 
care, as the duration of the diagnostic workup from the suspicion of neuromuscular disease to the genetic diagnosis is usually long.
The authors briefly present the most important aspects of cardiac investigations and therapeutic possibilities in the most im-
portant and most common neuromuscular diseases, including Duchenne and Becker muscular dystrophies, Emery-Dreifuss 
muscular dystrophy, and myotonic dystrophy type 1 (Steinert disease) and type 2.
Cardiac involvement in myotonic dystrophies deserves a more detailed discussion. Indeed, the most dangerous consequences 
of cardiac involvement in myotonic dystrophy type 1 include advanced atrioventricular conduction disturbances, with or without 
prior first degree atrioventricular block present for many years. It should be stressed that sudden cardiac death in patients with 
myotonic dystrophy type 1 is most commonly associated with advanced or complete atrioventricular block. In contrast, tachyar-
rhythmias are less frequent in Steinert disease but may also contribute to poor prognosis. Established risk factors for sudden 
cardiac death in this population should be borne in mine, i.e., non-sinus rhythm (particularly atrial fibrillation), PR interval pro-
longation > 240 ms, QRS duration > 120 ms, intermittent second- and third-degree atrioventricular block, and corrected QT in-
terval > 450 ms. A history of bradycardia-induced ventricular fibrillation is also considered an indication for prompt cardioverter- 
-defibrillator implantation in some countries, especially in patients with left ventricular systolic dysfunction.
As indicated by the authors, the risk of cardiac involvement in myotonic dystrophy type 2 is lower compared to type 1. Our experi-
ence indicates that atrioventricular and interventricular conduction disturbances are much less common, while supraventricular 
and ventricular arrhythmia is significantly more common in type 2 (except for atrial fibrillation which often accompanies myotonic 
dystrophy type 1, as also reported by others). For a proper understanding of cardiovascular complications of myotonic dystrophy 
type 2, it should be remembered that this disorder often manifests later in life. Hence, cardiac involvement related to the under-
lying neuromuscular disorder may coexist with pathologies resulting from normal aging and concomitant conditions such as dia-
betes type 2 which is typical for this type of dystrophy, thyroid disorders, or hypertension which is ubiquitous in later years of life.
The value of the article also stems from the discussion of the practical aspects of the proposed cardiac investigation, and a fig-
ure that clearly presents suggested cardiac investigations following the diagnosis of neuromuscular disease. It should be noted 
that a patient with neuromuscular disorder should have a good quality 12-lead electrocardiogram (ECG) recorded during each 
follow-up visit, with careful evaluation of all necessary parameters including corrected QT interval. Unfortunately, obtaining 
a good quality tracing is not always easy, and some patients are reluctant to undergo ECG recording due to their limited mobility.
Patients with neuromuscular disorders are usually regularly followed-up by neurologists, while cardiac evaluation is usually per-
formed after the genetic diagnosis is established, and only occasionally afterwards. It is thus important, as also highlighted in 
the commented article, that these patients should also undergo regular cardiological controls, optimally in specialized tertiary 
care centres cooperating with neurology experts.
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